Wall Street analysts expect that Amgen, Inc. (NASDAQ:AMGN) will announce earnings per share (EPS) of $3.45 for the current quarter, according to Zacks. Six analysts have issued estimates for Amgen’s earnings. The highest EPS estimate is $3.63 and the lowest is $3.04. Amgen posted earnings of $3.47 per share during the same quarter last year, which would suggest a negative year over year growth rate of 0.6%. The company is expected to announce its next quarterly earnings results after the market closes on Tuesday, April 30th.
On average, analysts expect that Amgen will report full-year earnings of $13.96 per share for the current year, with EPS estimates ranging from $13.30 to $14.75. For the next financial year, analysts expect that the company will post earnings of $14.62 per share, with EPS estimates ranging from $11.60 to $15.99. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Amgen.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, beating the Zacks’ consensus estimate of $3.26 by $0.16. Amgen had a net margin of 35.35% and a return on equity of 66.74%. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $5.88 billion. During the same quarter in the prior year, the company posted $2.89 EPS.
A number of analysts recently issued reports on AMGN shares. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, April 15th. Citigroup increased their target price on shares of Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research report on Friday, January 4th. Goldman Sachs Group reissued a “buy” rating and set a $232.00 target price on shares of Amgen in a research report on Thursday, January 17th. Oppenheimer set a $224.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Sunday, January 27th. Finally, Royal Bank of Canada reissued a “neutral” rating on shares of Amgen in a research report on Friday, February 1st. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Amgen currently has an average rating of “Hold” and a consensus price target of $209.11.
NASDAQ AMGN opened at $177.47 on Thursday. The stock has a market cap of $109.31 billion, a PE ratio of 12.32, a P/E/G ratio of 2.17 and a beta of 1.21. Amgen has a 12 month low of $165.22 and a 12 month high of $210.19. The company has a debt-to-equity ratio of 2.36, a current ratio of 2.79 and a quick ratio of 2.57.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.27%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is presently 40.28%.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total value of $386,360.00. Following the completion of the transaction, the director now owns 15,092 shares in the company, valued at approximately $2,915,472.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 6,000 shares of company stock valued at $1,144,120. 0.27% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Amgen by 2.0% in the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock worth $8,979,621,000 after acquiring an additional 906,568 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in Amgen by 20,103.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after acquiring an additional 31,268,677 shares during the period. Northern Trust Corp boosted its holdings in Amgen by 4.7% in the 4th quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock worth $1,787,470,000 after acquiring an additional 408,675 shares during the period. Geode Capital Management LLC boosted its holdings in Amgen by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after acquiring an additional 482,760 shares during the period. Finally, Norges Bank purchased a new position in Amgen in the 4th quarter worth approximately $1,283,248,000. Hedge funds and other institutional investors own 79.18% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Risk Tolerance and Your Investment Decisions
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.